Breast and Ovarian Cancers: A Survey and Possible Roles for the Cell Surface Heparan Sulfate Proteoglycans

Journal of Histochemistry and Cytochemistry

Volumn 60, Issue 1, 2012, Pages 9-21

  Yoneda, Atsuko ^a   Lendorf, Maria E ^a   Couchman, John R ^a   Multhaupt, Hinke A B ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

carcinoma; glycosaminoglycan; glypican; heparan sulfate proteoglycan; syndecan

Indexed keywords

CARBOHYDRATE; GLYPICAN; GROWTH FACTOR; HEPARAN SULFATE; MORPHOGEN; PROTEOGLYCAN; SYNDECAN; PROTEOHEPARAN SULFATE; TUMOR MARKER;

BREAST CANCER; CARCINOGENESIS; CELL SURFACE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; TUMOR GROWTH; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; MUTATION; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; FEMALE; GLYPICANS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MUTATION; OVARIAN NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION; SYNDECANS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856637517     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155411428469     Document Type: Review

References (106)

1. Aikawa J-I,Grobe K,Tsujimoto M,Esko JD.Multiple isoenzymes of heparan sulfate/heparin GlcNAcN-deacetylase/GlcN N-sulfotransferase.J Biol Chem. 2001;276:5876-5882.
2. Alexander CM,Reichsman F,Hinkes MT,Lincecum J,Becker KA,Cumberledge S,Bernfield M.Syndecan-1 is required for Wnt-1 induced mammary tumorigenesis in mice.Nat Genet. 2000;25:329-332.
3. Allred DC.Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.Mod Pathol. 2010;23 (Suppl 2): S52-S59.
4. Antonnen A,Heikkila P,Kajanti M,Jalkanen M,Joensuu H.High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery.Lung Cancer. 2001;32:297-305.
5. Arvatz G,Shafat I,Levy-Adam F,Ilan N,Vlodavsky I.The heparanase system and tumor metastasis: is heparanase the seed and soil?.Cancer Metastasis Rev. 2011;30:253-268.
6. Baba F,Swartz K,van Eickhoff BR,Zhang Y,Wolberg W,Friedl A.Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.Brest Cancer Res Treat. 2006;98:91-98.
7. Baciu PC,Goetinck PF.Protein kinase C regulates the recruitment of syndecan-4 into focal contacts.Mol Biol Cell. 1995;6:1503-1513.
8. Backen AC,Cole CL,Lau SC,Clamp AR,McVey RM,Gallagher JT,Jayson GC.Heparan sulphate synthetic and editing enzymes in ovarian cancer.Br J Cancer. 2007;96:1544-1548.
9. Bass MD,Roach KA,Morgan MR,Mostafavi-Pour Z,Schoen T,Muramatsu T,Mayer U,Ballestrem C,Spatz JP,Humphries MJ.Sydnecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix.J Cell Biol. 2007;177:527-538.
10. Bell DA.Origins and molecular pathology of ovarian cancer.Mod Pathol. 2005;18:19-32.
11. Bell KA,Kurman RJ.A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary.Am J Surg Pathol. 2000;24:1465-1479.
12. Bergamaschi A,Kim YH,Wang P,Sorlie T,Hernandez-Boussard T,Lonning PE,Tibshirani R,Borresen-Dale AL,Pollack JR.Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.Genes Chromosomes Cancer. 2006;45:1033-1040.
13. Bharwani N,Reznek RH,Rockall AG.Ovarian cancer management: the role of imaging and diagnostic challenges.Eur J Radiol. 2011;78:41-51.
14. Bhoola S,Hoskins WJ.Diagnosis and management of epithelial ovarian cancer.Obstet Gynecol. 2006;107:1399-1410.
15. Bild AH,Yao G,Chang JT,Wang Q,Potti A,Chasse D,Joshi MB,Harpole D,Lancaster JM,Berchuck A, et al.Oncogenic pathway signatures in human cancers as a guide to targeted therapies.Nature. 2006;439:353-357.
16. Bishop JR,Schuksz M,Esko JD.Heparan sulphate proteoglycans fine-tune mammalian physiology.Nature. 2007;446:1030-1037.
17. Capurro MI,Xu P,Shi W,Li F,Jia A,Filmus J.Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding.Dev Cell. 2008;14:700-711.
18. Chin K,DeVries S,Fridlyand J,Spellman PT,Roydasgupta R,Kuo WL,Lapuk A,Neve RM,Qian Z,Ryder T, et al.Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.Cancer Cell. 2006;10:529-541.
19. Choi C,Kim MH,Juhng SW.Loss of heterozygosity on chromosome XP22.2-p22.13 and Xq26.1-q27.1 in human breast carcinomas.J Korean Med Sci. 1998;13:311-316.
20. Choi Y,Kim H,Chung H,Hwang JS,Shin JA,Oh ES.Syndecan-2 regulates cell migration in colon cancer cells through Tiam1-mediated Rac activation.Biochem Biophys Res Commun. 2010;391:921-925.
21. Christie M,Oehler MK.Molecular pathology of epithelial ovarian cancer.J Br Menopause Soc. 2006;12:57-63.
22. Couchman JR.Syndecans: proteoglycan regulators of cell-surface microdomains?.Nat Rev Mol Cell Biol. 2003;4:926-937.
23. Couchman JR.Transmembrane signaling proteoglycans.Annu Rev Cell Dev Biol. 2010;26:89-114.
24. Daly M,Obrams GI.Epidemiology and risk assessment for ovarian cancer.Semin Oncol. 1998;25:255-264.
25. Davies EJ,Blackhall FH,Shanks JH,David G,McGown AT,Swindell R,Slade RJ,Martin-Hirsch P,Gallagher JT,Jayson GC.Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.Clin Cancer Res. 2004;10:5178-5186.
26. De Cat B,Muyldermans SY,Coomans C,Degeest G,Vanderschueren B,Creemers J,Biemar F,Peers B,David G.Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements.J Cell Biol. 2003;163:625-635.
27. Dews IC,Mackenzie KR.Transmembrane domains of the syndecan family of growth factor coreceptors display a hierarchy of homotypic and heterotypic interactions.Proc Natl Acad Sci U S A. 2007;104:20782-20787.
28. Ding K,Lopez-Burks M,Sanchez-Duran JA,Korc M,Lander AD.Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells.J Cell Biol. 2005;171:729-738.
29. Dubash AD,Menold MM,Samson T,Boulter E,Garcia-Mata R,Doughman R,Burridge K.Focal adhesions: new angles on an old structure.Int Rev Cell Mol Biol. 2009;277:1-65.
30. Dumitrescu RG,Shields PG.The etiology of alcohol-induced breast cancer.Alcohol. 2005;35:213-225.
31. Echtermeyer F,Streit M,Wilcox-Adelman S,Saoncella S,Denhez F,Detmar M,Goetinck P.Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4.J Clin Invest. 2001;107:R9-R14.
32. Esheba GE,Pate LL,Longacre TA.Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.Am J Surg Pathol. 2008;32:600-607.
33. Esko JD,Selleck SB.Order out of chaos: assembly of ligand binding sites in heparan sulfate.Annu Rev Biochem. 2002;71:435-471.
34. Fears CY,Gladson CL,Woods A.Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells.J Biol Chem. 2006;281:14533-14536.
35. Filmus J,Capurro M,Rast J.Glypicans.Genome Biol. 2008;9:224.
36. Fujiya M,Watari J,Ashida T,Honda M,Tanabe H,Fujiki T,Saitoh Y,Kohgo Y.Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.Jpn J Cancer Res. 2001;92:1074-1081.
37. Fuster MM,Esko JD.The sweet and sour of cancer: glycans as novel therapeutic targets.Nat Rev Cancer. 2005;5:526-542.
38. Gemignani ML,Schlaerth AC,Bogomolniy F,Barakat RR,Lin O,Soslow R,Venkatraman E,Boyd J.Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.Gynecol Oncol. 2003;90:378-381.
39. Gonzalez AD,Kaya M,Shi W,Song H,Testa JR,Penn LZ,Filmus J.OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner.J Cell Biol. 1998;141:1407-1414.
40. Harvey JM,Clark GM,Osborne CK,Allred DC.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.J Clin Oncol. 1999;17:1474-1481.
41. Hennessy BT,Coleman RL,Markman M.Ovarian cancer.Lancet. 2009;374:1371-1382.
42. Iozzo RV,Zoeller JJ,Nyström A.Basement membrane proteoglycans: modulators par excellence of cancer growth and metastasis.Mol Cells. 2009;27:503-513.
43. Jemal A,Siegel R,Ward E,Hao Y,Xu J,Thun MJ.Cancer statistics, 2009.CA Cancer J Clin. 2009;59:225-249.
44. Kamangar F,Dores GM,Anderson WF.Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.J Clin Oncol. 2006;24:2137-2150.
45. Karamanos NK,Vanky P,Tzanakakis GN,Hjerpe A.High performance capillary electrophoresis method to characterize heparin and heparan sulfate disaccharides.Electrophoresis. 1996;17:391-395.
46. Keum E,Kim Y,Kim J,Kwon S,Lim Y,Han I,Oh ES.Syndecan-4 regulates localization, activity and stability of protein kinase Cα.Biochem J. 2004;378:1007-1014.
47. Kim H,Wu R,Cho KR,Thomas DG,Gossner G,Liu JR,Giordano TJ,Shedden KA,Misek DE,Lubman DM.Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.Proteomics Clin Appl. 2008;2:571-584.
48. Kirkpatrick CA,Selleck SB.Heparan sulfate proteoglycans at a glance.J Cell Sci. 2007;120:1829-1832.
49. Kousidou OC,Berdiaki A,Kletsas D,Zafiropoulos A,Theiocharis AD,Tzanakakis GN,Karamanos NK.Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells.Mol Oncol. 2008;2:223-232.
50. Kreuger J,Perez L,Giraldez AJ,Cohen SM.Opposing activities of Dally-like glypican at high and low levels of Wingless morphogen activity.Dev Cell. 2004;7:503-512.
51. Kreuger J,Spillmann D,Li JP,Lindahl U.Interactions between heparan sulfate and proteins: the concept of specificity.J Cell Biol. 2006;174:323-327.
52. Kurman RJ,Visvanathan K,Roden R,Wu TC,Shih IM.Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.Am J Obstet Gynecol. 2008;198:351-356.
53. La VC,Bosetti C,Lucchini F,Bertuccio P,Negri E,Boyle P,Levi F.Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975.Ann Oncol. 2010;21:1323-1360.
54. Lee D,Oh ES,Woods A,Couchman JR,Lee W.Solution structure of a syndecan-4 cytoplasmic domain and its interaction with phosphatidylinositol 4,5 bisphosphate.J Biol Chem. 1998;273:13022-13029.
55. Lendorf ME,Manon-Jensen T,Kronqvist P,Multhaupt HA,Couchman JR.Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma.J Histochem Cytochem. 2011;59:615-629.
56. Li CI,Malone KE,Porter PL,Weiss NS,Tang MT,Cushing-Haugen KL,Daling JR.Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.JAMA. 2003;289:3254-3263.
57. Lin H,Huber R,Schlessinger D,Morin PJ.Frequent silencing of the GPC3 gene in ovarian cancer cell lines.Cancer Res. 1999;59:807-810.
58. Lin X.Functions of heparan sulfate proteoglycans in cell signaling during development.Development. 2004;131:6009-6021.
59. Lindahl U,Li JP.Interactions between heparan sulfate and proteins: design and functional implications.Int Rev Cell Mol Biol. 2009;276:105-159.
60. Longley RL,Woods A,Fleetwood A,Cowling GJ,Gallagher JT,Couchman JR.Control of morphology, cytoskeleton and migration by syndecan-4.J Cell Sci. 1999;112:3421-3431.
61. Lundin M,Nordling S,Lundin J,Isola J,Wiksten JP,Haglund C.Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer.Oncology. 2005;68:306-313.
62. Maeda D,Ota S,Takazawa Y,Aburatani H,Nakagawa S,Yano T,Taketani Y,Kodama T,Fukayama M.Glypican-3 expression in clear cell adenocarcinoma of the ovary.Mod Pathol. 2009;22:824-832.
63. Manon-Jensen T,Itoh Y,Couchman JR.Proteoglycans in health and disease: the multiple roles of syndecan shedding.FEBS J. 2010;277:3876-3889.
64. Matsuda K,Maruyama H,Guo F,Kleeff J,Itakura J,Matsumoto Y,Lander AD,Korc M.Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.Cancer Res. 2001;61:5562-5569.
65. Modrowski D,Orosco A,Thévenard J,Fromigué O,Marie PJ.Syndecan-2 overexpression induces osteosarcoma cell apoptosis: implication of syndecan-2 cytoplasmic domain and JNK signaling.Bone. 2005;37:180-189.
66. Mohsin SK,Weiss H,Havighurst T,Clark GM,Berardo M,Roanh LD,To TV,Qian Z,Love RR,Allred DC.Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study.Mod Pathol. 2004;17:1545-1554.
67. Morgan MR,Humphries MJ,Bass MD.Synergistic control of cell adhesion by integrins and syndecans.Nat Rev Mol Cell Biol. 2007;8:957-969.
68. Morimoto-Tomita M,Uchimura K,Bistrup A,Lum DH,Egeblad M,Boudreau N,Werb Z,Rosen SD.Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer.Neoplasia. 2005;7:1001-1010.
69. Mullan PB,Millikan RC.Molecular subtyping of breast cancer: opportunities for new therapeutic approaches.Cell Mol Life Sci. 2007;64:3219-3232.
70. Multhaupt HA,Yoneda A,Whiteford JR,Oh ES,Lee W,Couchman JR.Syndecan signaling: when, where and why?.J Physiol Pharmacol. 2009;60 (Suppl 4): 31-38.
71. Mundhenke C,Meyer K,Drew S,Friedl A.Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas.Am J Pathol. 2002;160:185-194.
72. Murphy KJ,Merry CL,Lyon M,Thompson JE,Roberts IS,Gallagher JT.A new model for the domain structure of heparan sulfate based on the novel specificity of K5 lyase.J Biol Chem. 2004;279:27239-27245.
73. Mythreye K,Blobe GC.Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.Cell Signal. 2009;21:1548-1558.
74. Park H,Kim Y,Lim Y,Han I,Oh ES.Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells.J Biol Chem. 2002;277:29730-29736.
75. Payne SJ,Bowen RL,Jones JL,Wells CA.Predictive markers in breast cancer-the present.Histopathology. 2008;52:82-90.
76. Perou CM,Sørlie T,Eisen MB,van de,Rijn M,Jeffrey SS,Rees CA,Pollack JR,Ross DT,Johnsen H,Akslen LA, et al.Molecular portraits of human breast tumours.Nature. 2000;406:747-752.
77. Peters MG,Farias E,Colombo L,Filmus J,Puricelli L,Bal de Kier Joffe E.Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model.Breast Cancer Res Treat. 2003;80:221-232.
78. Pilia G,Highes-Benzie RM,MacKenzie A,Baybayan P,Chen EY,Huber R,Neri G,Cao A,Forabosco A,Schlessinger D.Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome.Nat Genet. 1996;12:241-247.
79. Ricciardelli C,Rodgers RJ.Extracellular matrix of ovarian tumors.Semin Reprod Med. 2006;24:270-282.
80. Rosen PP. 2001. Rosen's Breast Pathology.2nd ed.Philadelphia: Lippincott Williams & Wilkins.
81. Rosen SD,Lemjabbar-Alaoui H.Sulf2: an extracellular modulator of cell signaling and a cancer target candidate.Expert Opin Ther Targets. 2010;14:935-949.
82. Ross JS,Linette GP,Stec J,Clark E,Ayers M,Leschly N,Symmans WF,Hortobagyi GN,Pusztai L.Breast cancer biomarkers and molecular medicine: part II.Expert Rev Mol Diagn. 2004;4:169-188.
83. Ross JS,Symmans WF,Pusztai L,Hortobagyi GN.Breast cancer biomarkers.Adv Clin Chem. 2005;40:99-125.
84. Sainsbury JR,Anderson TJ,Morgan DA.ABC of breast diseases: breast cancer.BMJ. 2000;321:745-750.
85. Sanderson RD,Yang Y.Syndecan-1: a dynamic regulator of the myeloma environment.Clin Exp Metastasis. 2008;25:149-159.
86. Schmeler KM,Sun CC,Bodurka DC,White KG,Soliman PT,Uyei AR,Erlichman JL,Arun BK,Daniels MS,Rimes SA, et al.Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.Obstet Gynecol. 2006;108:515-520.
87. Seidman JD,Kurman RJ.Pathology of ovarian carcinoma.Hematol Oncol Clin North Am. 2003;17:909-925.
88. Shih IM,Kurman RJ.Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.Am J Pathol. 2004;164:1511-1518.
89. Shinyo Y,Kodama J,Hasengaowa,Kusumoto T,Hiramatsu Y.Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer.Gynecol Oncol. 2005;96:776-783.
90. Singer G,Oldt R,Cohen Y,Wang BG,Sidransky D,Kurman RJ,Shih IM.Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.J Natl Cancer Inst. 2003;95:484-486.
91. Skidmore MA,Guimond SE,Rudd TR,Fernig DG,Turnbull JE,Yates EA.The activities of heparan sulfate and its analogue heparin are dictated by biosynthesis, sequence and conformation.Conn Tiss Res. 2008;49:140-144.
92. Song HH,Shi W,Filmus J.OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2.J Biol Chem. 1997;272:7574-7577.
93. Song HH,Shi W,Xiang YY,Filmus J.The loss of glypican-3 induces alterations in Wnt signaling.J Biol Chem. 2005;280:2116-2125.
94. Sorlie T,Perou CM,Tibshirani R,Aas T,Geisler S,Johnsen H,Hastie T,Eisen MB,Van de Rijn M,Jeffrey SS, et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci U S A. 2001;98:10869-10874.
95. Stadlmann S,Gueth U,Baumhoer D,Moch H,Terracciano L,Singer G.Glypican-3 expression in primary and recurrent ovarian carcinomas.Int J Gynecol Pathol. 2007;26:341-344.
96. Steigmann P,Molitor A,Fllert S,Jäckle H,Vorbrüggen G. Heparan sulfate proteoglycan syndecan promotes axonal and myotube guidance by slit/robo signaling.Curr Biol. 2004;14:225-230.
97. Subramaniam DS,Isaacs C.Utilizing prognostic and predictive factors in breast cancer.Curr Treat Options Oncol. 2005;6:147-159.
98. Tavassoli FA.1999. Pathology of the Breast. 2nd ed.Stamford, CT: Appleton Lange.
99. Theocharis AD,Skandalis SS,Tzanakakis GN,Karamanos NK.Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting.FEBS J. 2010;277:3904-3923.
100. Umezu T,Shibata K,Kajiyama H,Yamamoto E,Nawa A,Kikkawa F.Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.J Clin Pathol. 2010;63:962-966.
101. Vargo-Gogola T,Rosen JM.Modelling breast cancer: one size does not fit all.Nat Rev Cancer. 2007;7:659-672.
102. Vlodavsky I,Beckhove P,Lerner I,Pisano C,Meirovitz A,Ilan N,Elkin M. 2011. Significance of heparanase in cancer and inflammation.Cancer Microenviron. 2011 Aug 3. [Epub ahead of print]
103. Woods A,Couchman JR.Syndecan-4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component.Mol Cell Biol. 1994;5:183-192.
104. Xiang YY,Ladeda V,Filmus J.Glypican-3 expression is silenced in human breast cancer.Oncogene. 2001;20:7408-7412.
105. Yan PS,Chen CM,Shi H,Rahmatpanah F,Wei SH,Caldwell CW,Huang TH.Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays.Cancer Res. 2001;61:8375-8380.
106. Zimmermann P,Zhang Z,Degeest G,Mortier E,Leenaerts I,Coomans C,Schulz J,N'Kuli F,Courtoy PJ,David G.Syndecan recycling is controlled by syntenin-PIP2 interaction and Arf6.Dev Cell. 2005;9:377-388.